Pavlovian Conditioned Approach, Goal-tracking, average magazine entry latency on day 3 of testing
Project: p50_shelly_flagel_2014
1 significantly associated model · 1 unique gene
| # | chr | p0 | p1 | # assoc genes | # joint models | best TWAS P | best SNP P | cond SNP P | % var exp | joint genes |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 17 | 53511716 | 54898754 | 1 | 1 | 2.3e-07 | 3.1e-07 | 1 | 100 | Cul2 |
p0: physical position of the start of the locus. p1: physical position of the end of the locus. # joint models: number of models selected by step-wise conditional analysis.
| Trait | chisq ratio | # genes+ | # genes++ | % genes++ | corr | corr P | genes |
|---|---|---|---|---|---|---|---|
| os_mean | 3.2 | 1 | 0 | 0 | 0 | 1 | Cul2 |
| Total sessions with >9 infusions | 3.8 | 1 | 0 | 0 | 0 | 1 | Cul2 |
| Velocity during novelty place preference test | 5.3 | 1 | 0 | 0 | 0 | 1 | Cul2 |
| pavca_mi_d3_magazine_ncs | 8.2 | 1 | 0 | 0 | 0 | 1 | Cul2 |
| tautz: manual_spc15 | 3.1 | 1 | 0 | 0 | 0 | 1 | Cul2 |
| tautz: manual_spc12 | 7.5 | 1 | 0 | 0 | 0 | 1 | Cul2 |
| tautz: manual_mcs | 6.2 | 1 | 0 | 0 | 0 | 1 | Cul2 |
| tautz: manual_mpc19 | 4.2 | 1 | 0 | 0 | 0 | 1 | Cul2 |
| tautz: manual_spc10 | 7.1 | 1 | 0 | 0 | 0 | 1 | Cul2 |
| dd_expon_k | 4.6 | 1 | 0 | 0 | 0 | 1 | Cul2 |
| Delay discounting AUC-traditional | 4.0 | 1 | 0 | 0 | 0 | 1 | Cul2 |
| Area under the delay curve | 4.0 | 1 | 0 | 0 | 0 | 1 | Cul2 |
| Liver sodium concentration | 5.7 | 1 | 0 | 0 | 0 | 1 | Cul2 |
chisq ratio: Average Chi2 statistic for the selected genes in the secondary trait, divided by the average statistic for all genes in the secondary trait. # genes+: Shared significant genes at Bonferroni correction. # genes++: Shared significant genes at transcriptome-wide significance. % genes++: Number of [++] genes as a percentage of primary trait’s total joint genes. corr: Correlation of effect sizes across the [+] genes.
| tissue | modality | # hits | % hits/tests | avg chisq |
|---|---|---|---|---|
| Adipose | alternative polyA | 0 | 0.00 | 1.38 |
| Adipose | alternative TSS | 0 | 0.00 | 1.29 |
| Adipose | gene expression | 0 | 0.00 | 1.25 |
| Adipose | isoform ratio | 0 | 0.00 | 1.33 |
| Adipose | intron excision ratio | 0 | 0.00 | 1.30 |
| Adipose | mRNA stability | 0 | 0.00 | 1.23 |
| BLA | alternative polyA | 0 | 0.00 | 1.25 |
| BLA | alternative TSS | 0 | 0.00 | 1.38 |
| BLA | gene expression | 0 | 0.00 | 1.25 |
| BLA | isoform ratio | 0 | 0.00 | 1.23 |
| BLA | intron excision ratio | 0 | 0.00 | 1.42 |
| BLA | mRNA stability | 0 | 0.00 | 1.23 |
| Brain | alternative polyA | 0 | 0.00 | 1.28 |
| Brain | alternative TSS | 0 | 0.00 | 1.42 |
| Brain | gene expression | 0 | 0.00 | 1.27 |
| Brain | isoform ratio | 0 | 0.00 | 1.29 |
| Brain | intron excision ratio | 0 | 0.00 | 1.37 |
| Brain | mRNA stability | 0 | 0.00 | 1.28 |
| Eye | alternative polyA | 0 | 0.00 | 0.96 |
| Eye | alternative TSS | 0 | 0.00 | 1.42 |
| Eye | gene expression | 0 | 0.00 | 1.23 |
| Eye | isoform ratio | 0 | 0.00 | 1.38 |
| Eye | intron excision ratio | 0 | 0.00 | 1.36 |
| Eye | mRNA stability | 0 | 0.00 | 1.35 |
| IL | alternative polyA | 0 | 0.00 | 1.26 |
| IL | alternative TSS | 0 | 0.00 | 1.67 |
| IL | gene expression | 0 | 0.00 | 1.25 |
| IL | isoform ratio | 0 | 0.00 | 1.48 |
| IL | intron excision ratio | 0 | 0.00 | 1.51 |
| IL | mRNA stability | 0 | 0.00 | 1.22 |
| LHb | alternative polyA | 0 | 0.00 | 1.35 |
| LHb | alternative TSS | 0 | 0.00 | 1.26 |
| LHb | gene expression | 0 | 0.00 | 1.27 |
| LHb | isoform ratio | 0 | 0.00 | 1.39 |
| LHb | intron excision ratio | 0 | 0.00 | 1.63 |
| LHb | mRNA stability | 0 | 0.00 | 1.23 |
| Liver | alternative polyA | 0 | 0.00 | 1.29 |
| Liver | alternative TSS | 0 | 0.00 | 1.39 |
| Liver | gene expression | 0 | 0.00 | 1.25 |
| Liver | isoform ratio | 0 | 0.00 | 1.30 |
| Liver | intron excision ratio | 0 | 0.00 | 1.32 |
| Liver | mRNA stability | 0 | 0.00 | 1.24 |
| NAcc | alternative polyA | 1 | 0.19 | 1.67 |
| NAcc | alternative TSS | 0 | 0.00 | 1.61 |
| NAcc | gene expression | 0 | 0.00 | 1.27 |
| NAcc | isoform ratio | 0 | 0.00 | 1.30 |
| NAcc | intron excision ratio | 0 | 0.00 | 1.43 |
| NAcc | mRNA stability | 0 | 0.00 | 1.19 |
| NAcc2 | alternative polyA | 0 | 0.00 | 1.15 |
| NAcc2 | alternative TSS | 0 | 0.00 | 1.41 |
| NAcc2 | gene expression | 0 | 0.00 | 1.28 |
| NAcc2 | isoform ratio | 0 | 0.00 | 1.31 |
| NAcc2 | intron excision ratio | 0 | 0.00 | 1.41 |
| NAcc2 | mRNA stability | 0 | 0.00 | 1.23 |
| OFC | alternative polyA | 0 | 0.00 | 1.28 |
| OFC | alternative TSS | 0 | 0.00 | 1.60 |
| OFC | gene expression | 0 | 0.00 | 1.27 |
| OFC | isoform ratio | 0 | 0.00 | 1.42 |
| OFC | intron excision ratio | 0 | 0.00 | 1.54 |
| OFC | mRNA stability | 0 | 0.00 | 1.26 |
| PL | alternative polyA | 0 | 0.00 | 1.26 |
| PL | alternative TSS | 0 | 0.00 | 1.72 |
| PL | gene expression | 0 | 0.00 | 1.27 |
| PL | isoform ratio | 0 | 0.00 | 1.31 |
| PL | intron excision ratio | 0 | 0.00 | 1.52 |
| PL | mRNA stability | 0 | 0.00 | 1.16 |
| PL2 | alternative polyA | 0 | 0.00 | 1.22 |
| PL2 | alternative TSS | 0 | 0.00 | 1.45 |
| PL2 | gene expression | 0 | 0.00 | 1.27 |
| PL2 | isoform ratio | 0 | 0.00 | 1.31 |
| PL2 | intron excision ratio | 0 | 0.00 | 1.41 |
| PL2 | mRNA stability | 0 | 0.00 | 1.22 |
avg chisq: Average Chi2 (squared Z-score) across all models in this panel for this trait.